Plasminogen-activator inhibitor type 1 and coronary artery disease.

By H. Kohler, P. Grant. New England Journal of Medicine, 2000

856 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management (2011, background): “Elevated triglycerides are linked with raised concentrations of fibrinogen and coagulation factors VII and XII, and with impaired fibrinolysis as determined by enhanced gene expression and concentrations of plasminogen activator inhibitor-1.(56,57)”
Androgens and coronary artery disease. (2003, background): “In addition, common genetic polymorphisms interact with classic risk factors to negate the protective genetic effects or enhance the deleterious actions of environmental or lifestyle variables (10).”
Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. (2008, background): “Results from prospective and Case–Control studies have pointed towards a possible contribution of coagulation factors and proteins of the fibrinolytic system in the development of vascular events.(106) PAI-1 is a primary regulator of fibrinolysis and is largely produced by visceral(107) adipocytes u”
A Comprehensive Review on Metabolic Syndrome (2014, neutral): “Lifestyle modification treatment should be delivered by amultidisciplinary approach (Table 4) and a team composed of physicians and nonphysician health professionals, such as dieticians or professionalswith amaster degree in exercise physiology, behavioural psychology, or health education [127].”